Description
PA452, retinoic X receptor (RXR) specific antagonist, inhibits the effect of Retinoic acid (RA) on Th1/Th2 development.
Product information
CAS Number: 457657-34-0
Molecular Weight: 439.59
Formula: C26H37N3O3
Chemical Name: 2-{[3-(hexyloxy)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl](methyl)amino}pyrimidine-5-carboxylic acid
Smiles: CCCCCCOC1=CC2=C(C=C1N(C)C1N=CC(=CN=1)C(O)=O)C(C)(C)CCC2(C)C
InChiKey: JJUUTJCZMGZJDZ-UHFFFAOYSA-N
InChi: InChI=1S/C26H37N3O3/c1-7-8-9-10-13-32-22-15-20-19(25(2,3)11-12-26(20,4)5)14-21(22)29(6)24-27-16-18(17-28-24)23(30)31/h14-17H,7-13H2,1-6H3,(H,30,31)
Technical Data
Appearance: Solid Power
Purity: ≥98% (or refer to the Certificate of Analysis)
Solubility: DMSO : 40 mg/mL (90.99 mM; Need ultrasonic and warming).
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life: ≥12 months if stored properly.
Stock Solution Storage: 0 - 4 oC for 1 month or refer to the Certificate of Analysis.
Drug Formulation: To be determined
HS Tariff Code: 382200
How to use
In Vitro:
PA452 inhibits the Troglitazone (TZ)-induced CK13 expression. PA452 (0.01, 0.1, and 1 μM) inhibits RXR in normal human urothelial (NHU) cells.
Products are for research use only. Not for human use.
Payment & Security
Your payment information is processed securely. We do not store credit card details nor have access to your credit card information.